The acquisition will cost around $2 billion at $21 per share, with an additional $400 million to be paid to Fusion if the biotech firm satisfies specific requirements.
This move is part of AstraZeneca’s cancer treatment pipeline expansion, as Fusion is focused on next-generation radioconjugates that kill cancer cells more accurately than chemotherapy, reducing risk for healthy cells.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
